Loading…
Based on limited metadata, The Anthos Group, Inc. received an FDA Warning Letter in November 2022 from the Center for Drug Evaluation and Research (CDER) for refusing to provide access to and copying of records. The violation appears to involve non-compliance with FDA record access requirements, which are critical for regulatory oversight and inspections. While the product category is listed as "Other," the involvement of CDER indicates the company's operations fall under drug evaluation and research oversight.